WORLD INTELLECTUAL PROPERTY ORGANIZATION
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)
(51) International Patent Classification 5
(11) Internationa) Publication Number:
(43) International Publication Date:
25 July 1991 (25.07.91)
(21) International Application Number: PCT/US 9 1/00074
(22) International Filing Date: 4 January 1991 (04.01.91)
(30) Priority data:
8 January 1990 (08.01.90) US
(71) Applicant: GENENTECH, INC. [US/US]; 460 Point San
Bruno Boulevard, South San Francisco, CA 94080 (US).
(72) Inventors: ATTIE, Kenneth, M ; 326 Carl Street, San
Francisco, CA 94117 (US). MATHER, Jennie, P. ; 269
La Prenda Drive, Millbrae, CA 94030 (US).
(74) Agents: HASAK, Janet, E. et al.; Genentech, Inc., 460
Point San Bruno Boulevard, South San Francisco, CA
(81) Designated States: AT (European patent), AU, BE (Euro
pean patent), CA, CH (European patent), DE (Euro-
pean patent), DK (European patent), ES (European pa-
tent), FR (European patent), GB (European patent), GR
(European patent), IT (European patent), JP, LU (Euro-
pean patent), NL (European patent), SE (European pa-
With international search report.
Before the expiration of the time limit for amending the
claims and to be republished in the event of the receipt of
(54) Title: METHOD FOR INCREASING FERTILITY IN MALES
A method is provided for increasing fertility in a male mammal exhibiting germinal epithelium failure comprising adminis-
tering to the mammal an effective amount of activin. Preferably, the administration is to the testis of the mammal.
FOR THE PURPOSES OF INFORMATION ONLY
Codes used to identify States party to the PCT on the front pages of pamphlets publishing international
applications under the PCT.
. Central African Republic
Democratic People's Republic
C6le d 'I voire
Republic of Korea
United States of America
W0 91/10444 PCT/US91/00074
METHOD FOR INCREASING FERTILITY IN MALES
Field of the Invention
This invention relates to a method for increasing fertility in male mammals having a low
5 Description of Related Art
Inhibin is a glycoprotein produced by diverse tissues, including the gonads, pituitary,
brain, bone marrow, placenta, and adrenal gland. It was initially identified by its ability to
inhibit the secretion of follicle stimulating hormone (FSH) by the pituitary. De Jong and
Sharpe, Nature , 2£3_: 71-72 (1 976); Schwartz and Channing. Proc. Natl. Acad. Sci. USA 74:
5721-5724 (1977). Such preferential regulation of the gonadotropin secretion has generated
a great deal of interest and prompted many laboratories in the past fifty years to attempt to
isolate and characterize this substance from extracts of testis, spermatozoa, rete testis fluid,
seminal plasma, and ovarian follicular fluid using various bioassays. Rivier et a/., Biochem.
Biophys. Res. Commiin , 133_: 1 20 (1 985); Ling et el., Proc. Natl. Arad. Sci. USA £2: 721 7
15 (1985); Fukuda et el.. Mol. Cell Endocrjnol,, M : 55 (1985). The structure of inhibin,
characterized from several species, consists of two disulfide-linked subunits: an a and either
ajJAora 0B chain.
After the identification of inhibin. activin was shown to exist in follicular fluid as a
naturally occurring substance. Activin was found to be capable of stimulating FSH release
by rat anterior pituitary cells. Vale et a/., Nature. 221: 776-779 (1 986); Ling et ah, Nature.
321: 779-782 (1 986). Activin consists of a homodimer or heterodimer of inhibin 0 subunits,
which may be ft or ft subunits. Vale et a/.. Recent Proo. Hnrm Roc M: 1 . 34 (1988)
There is 95-1 00% amino acid conservation of fi subunits among human, porcine, bovine, and
rat activins. The 0 A and 0 B subunits within a given species are about 64-70% homologous.
The activin /? A and ft homodimers ("Activin A" and "Activin B," respectively) have been
identified in follicular fluid, and both molecules have been cloned and their genes expressed.
Mason et a/.. Biochem. Biophvs. Res, Cnmm^n j^5 : g 57 (1986); EP Pub. No. 222,491
published May 20. 1987; Mason eta/., Molecular Enrinrrinnl 3: 1352-1358 (1989). The
complete sequence of the ft subunit is published in Serono Symposium Publications, entitled
■Inhibin- Non-Steroidal Regulation of Follicle Stimulating Hormone Secretion", eds. H:G.
Burger et a/., abstract by A.J. Mason et a/., vol. 42. pp. 77-88 (Raven Press: New York
1987), entitled "Human Inhibin and Activin: Structure and Recombinant Expression in
Both Activin A and Activin AB. but thus far not Activin B, have been isolated from
natural sources. Activin mRNA (ft and 0 B subunits). bioactivity. and immunoactivity have
been reported to be produced by testicular Leydig cells from immature rat and pig. Lee-er el.,
Ssienss, 243: 396-398 (1 989); Lee et al., in Serono Symposium Publications, entitled "The
Molecular and Cellular Endocrinology of the Testis." Cooke and Sharpe, eds.. Vol. SO (Raven
Press: New York, 1 988), p. 21-27. Activin A has been found recently to have erythropoietic-
stimuiating activity as well as FSH-releasing activity. See EP Publ. No. 210,461 published
February 4, 1987 (where the protein is called BUF-3), Eto et aL, Biochem. Biophvs. Res.
Commun. , 142: 1095-1103 (1987) and Murata et aL, Proc. Natl. Acad, Sci. U.S.A., 85:
5 2434-2438 (1988) (where the activin is called EDF), and Yu et aL. Nature . 330 : 765-767
(1987) (where the activin is called FRP). In these systems, inhibin antagonized the actions
A protein known as follicle or follicular regulatory protein having a molecular weight
of 1 2,00 to 1 5,000 is found to inhibit aromatase levels, modulate the formation of mature
10 ova substantially independently of steroidal sex hormones, and reduce fertility in the male rat
by systemic treatment. It does not directly affect the gonadotropin output of the pituitary.
See U.S. Pat. No. 4,734,398; Tsutsumi et aL, Fertil. Steril.. 47: 689 (1987); Lew et aL,
Obstet. and GvnecoL 70: 157-162 (1987); diZerega et aL, Meiotic Inhibition: Molecular
Control of Meiosis (Alan R. Uss, Inc., 1988), p. 201-226; diZerega et aL, J. Steroid
15 Biochem.. 27: 375-383 (1987); Montz et aL, Am. J. Obstet. GvnecoL. 436-441 (Feb. 15,
1984); Ahmad et aL, the Anatomical Record. 224 : 508-513 (1989). This protein, also
named FRP, has been purified and partially sequenced, and is not related in any way to the
FSH-releasing protein known as activin, referred to as FRP by the Salk researchers in their
20 Recently, the expression of inhibin subunits, each encoded by a separate gene, was
demonstrated in several tissues in addition to ovary and testis. Inhibin a, 0 A , and 0 B mRNAs
were detected in placental, pituitary, adrenal, bone marrow, kidney, spinal cord, and brain
tissues. Meunier et aL, Proc. Natl. Acad. Sci. USA. £5: 247 (1988). The expression of the
inhibin subunit mRNAs varied by several-fold in a tissue-specific manner, suggesting different
25 functions for these proteins depending on their pattern of association and their site of
Inhibin and activin are members of a family of growth and differentiation factors. The
prototype of this family is transforming growth factor-beta (TGF-/?) (Derynck et aL, Nature,
316: 701-705 (1985)), which, according to one source, possesses FSH-releasing activity.
30 Ying et aL, Biochem. Biophvs. Res. Commun.. 135: 950-956 (1 986). Other members of the
TGF-A family include the Mullerian inhibitory substance, the fly decapentaplegic gene
complex, and the product of Xenoous Vg-1 mRNA.
In the human, growing preovulatory follicles and corpus luteum secrete inhibin into the
circulation in response to FSH stimulation. Lee and Gibson, Aust. J. Biol. Sci.. 3g : 1 1 5-120
35 (1 985); McLachlan et aL, Fertil. Steril.. 48: 1 001 (1 987). Thus, inhibin-related peptides play
important roles in the modulation of gonadal functions via a pituitary feedback loop. In rat
primary cultures of testis cells and ovarian thecal-interstitial cells, inhibin has been reported
to enhance androgen biosynthesis stimulated by leutinizing hormone (LH), whereas activin
WO 91/10444 PCT/US91/00074
suppresses androgen production. Hsueh et al.. Proc. Natl. Acad. Sci. USA. £4j 5082-5086
(1987). Other workers have been unable to repeat these observations. deKretser and
Robertson, Biology of Renmrii.rtinn 4Q: 33.47 (1 989), particularly p. 41 . Inhibitory effects
of TGF-0 on Leydig cell steroidogenesis have also been described. Lin et al., Biochem.
5 Bjppfrys. pes. Commun., Jifi: 387 (1987); Fauser and Hsueh, Life Sci.. 4^: 1363 (1988);
Avallet et a/., Biochem. Biophvs. Res. Cnmmim. 14§: 575 (1 987). In granulosa cells, activin
has been reported to inhibit (and TGf-0 to enhance) progesterone production. Ignotz and
Massague, J. Biol, Chem.., 261: 4337 (1986). In primary cultures of granulosa cells, activin
and inhibin as well as TGF-0 were found to affect hormone synthesis and secretion, each in
10 a different fashion. Adashi and Resnick, Endocrinology. 119; 1879 (1986); Ying et a/.,
Biochem. Bipphvs. Res. Common. , JL3£: 969 (1 986); Hutchinson et al., Biochem. Bionhvs.
Res. Commun. , 14£: 1405 (1987); Mondschein er at., Endocrinology. 123 : 1970 (1988);
Feng et el., J. Biol, Chem., 26J.: 14167 (1986). These molecules have both positive and
negative effects on FSH-dependent granulosa cell function. Carson et al.. J. Reprod. Fert..
1 5 8J5: 735-746 (1 989). Also suggested is that individual members of the TGF-0/inhibin gene
family regulate ovarian function, not only by direct action on follicle cells, but also indirectly
by influencing the production rate of other members of that family. Zhiwen et al., Molecular
and Cellular Endocrinology £g : 161-166 (1988).
Activin A and inhibin were reported to modulate growth of two gonadal cell lines,
20 suggesting that these proteins may regulate proliferation as well as functions of gonadal cells.
Gonzalez-Manchon and Vale, Endocrinology. 1666-1672 (1989). The secretion of
inhibin by the corpus luteum has been proposed to suppress the concentration of FSH in the
luteal phase of the cycle and hence the inhibition of follicular development. Baird et al., Ann.
N. Y. Acad. Sri.. E41- 153-161 (1988).
25 a review article postulates that inhibin is at least one of the factors that determines
the number of follicles destined to ovulate, and that interference with the action of inhibin
might contribute to the regulation of fertility. De Jong, Phvsiol. Rpv. 68: 555 (1 988). Many
investigators have speculated that due to its FSH-inhibiting effect, inhibin may be useful in
male and female contraception. Sheth and Moodbidri, Adv. Contracept . 2: 131-139 (1986);
30 Hndlay. Fertil. Steril., 46: 770 (1 986); van Dissel-Emiliani er al. . Endocrinology. 125 : 1 898-
1903 (1989); Bhasin eta/., Endocrinology, 124: 987991 (1989). However, another author
doubts that inhibin can inhibit spermatogenesis (citing Bremner et al., J. Clin. Invest.. gg :
1044 (1981)). and states that inhibin might also have some direct stimulatory effects on
spermatogenesis. Baker et al.. Clin. Rcnrnri. ^ F fn , g : 161-174 (1983).
35 The distributions of the 0, 0„ and 0 B subunits of inhibin/activin polypeptides were
studied in the testis of rats. It was found that in the rat testis, both Sertoli and interstitial
cells produce inhibin/activin subunits, and the o and 0 subunits are produced by different
types of interstitial cells in immature rats. Roberts et al., Endocrinology . J2&: 2350 (1989).
Also it was found that immunoreactive inhibin subunits are present in multiple cells in the
testis and that the amounts of immunostainable subunits in the seminiferous epithelium are
differentially regulated. Shaha et aL. Endocrinology , 125: 1941 (1989).
Activin bioactivity has been reported to be secreted by interstitial cells in in vitro ,
5 while Sertoli cells secrete inhibin or a mixture of inhibin and activin. Lee et aL, in Serono
Symposium Publications, supra; Lee et aL, Science, supra.
Many substances produced in the testes have been shown to regulate testicular
function locally. Mather, in Mammalian Cell Culture, ed. J. Mather (Plenum Publishing Corp.
1984), p. 167-193. While inhibin and activin have primarily been considered as feedback
0 regulators of pituitary function, in light of recent data on multiple sites of production and
action in the testis, it seems likely that they may also play a role as local regulators of
Failure to conceive is a complaint that leads as many as one in six married couples to
seek medical attention. Of these couples, at least 40% will be discovered to have a male
5 factor deficiency. Approximately 61% of infertile men have hypospermatogenesis on
testicular biopsy. These patients have partial germinal epithelium failure and present with
oligospermia and normal testosterone levels. The etiology is often idiopathic, but may be
associated with antineoplastic agents, cryptorchidism, or varicoceles.
In the male, the maturation of immature germ cells into spermatozoa (spermatogenesis)
0 is thought to be regulated by the gonadotropins (LH and especially FSH) and androgens
(testosterone). The current treatments for male infertility due to oligospermia are based on
this assumption. These include induction of rebound from testosterone or anabolic androgen-
induced azospermia; administration of exogenous gonadotropins or gonadotropin releasing
hormone; use of clomiphene citrate or tamoxifen to stimulate endogenous gonadotropin
5 secretion; administration of low doses of mesterolone, an oral synthetic androgen; and use
of an aromatase inhibitor such as testolactone.
No study has conclusively established the benefit of these treatments, although one
report suggests that a statistically significant effect is exerted only by clomiphene citrate.
However, clomiphene has been shown to be problematic in the high doses used by women.
3 Furthermore, the gonadotropins and androgens may act primarily in an indirect manner, via
stimulation of Sertoli and/or Leydig cell factors that affect the germinal epithelium directly.
Accordingly, it is an object of the present invention to provide a method for increasing
fertility of men with oligospermia using a fertility agent that causes direct stimulation of
sperm production by local administration.
5 It is another object to provide a fertility agent to treat hypospermatogenesis that is
both safe and efficacious.
This object and other objects will be apparent to one of ordinary skill in the art.
Summar v of the Invention
The present invention provides a method of increasing fertility in a male mammal
exhibiting germinal epithelium failure comprising administering to the mammal an effective
amount of activin.
In another aspect, the invention provides a pharmaceutical composition for increasing
fertility in male mammals exhibiting germinal epithelium failure comprising an effective
amount of activin in a pharmaceutical^ acceptable carrier.
Brief Desc ription of the Drawings
Figure 1 shows graphs of the level of incorporation of 3H-thymidine after 24 hours, 48
hours and 72 hours of treatment of rat Sertoli and germ cell cocultures with added activin A
(A, 100 ng/mi), added inhibin (I, 100 ng/ml), or control (C). All conditions contained medium
plus 5F (which is insulin, 5 //g/ml; transferrin, 5 //g/ml; c-tocopherol, 5 //g/ml; EGF, 5 ng/ml;
and aproteinin, 25 //g/ml).
Figure 2A shows a graph of DNA flow cytometric quantification of inhibin-treated rat
Sertoli and germ cell cocultures at 48 hours compared with a control (5F). Figure 2B shows
a similar graph comparing activin treatment with a control (5F).
Description of the Preferred Embodiment^
As used herein, the term "activin" refers to homo- or heterodimers of 0 chains of
inhibin, prepro forms, and pro forms, together with glycosylation and/or amino acid sequence
variants thereof. After cleavage from the mature protein, the precursor portion may be non-
covalently associated with the mature protein. Activin A refers to activin with the two chains
of 0 A . Activin AB refers to activin with the chains 0 A and ft. Activin B refers to activin with
the two chains of 0 B .
The intact isolated prepro or prodomain or mature 0 A and 0 B sequences are suitably
synthesized by any means, including synthetic and/or recombinant means, but are preferably
synthesized in recombinant cell culture, for example, as described in U.S. Pat. No. 4,798,885
issued January 17, 1989.
It is within the scope hereof to employ activin from animals other than humans, for
example, porcine or bovine sources, to treat humans. For example, the nucleotide and
deduced amino acid sequences of the porcine activin 0 chain are found in Figures 2A and 2B
of U.S. Pat. No. 4,798,885, supra. Likewise, if it is desirable to treat other mammalian
species such as domestic and farm animals and sports, zoo, or pet animals, human activin,
as well as activin from other species, is suitably employed.
Generally, amino acid sequence variants will be substantially homologous with the
relevant portion of the mammalian 0 chain sequences set forth in, e.g., U.S. Pat. No.
4,798,885, supra. Substantially homologous means that greater than about 60% of the
primary amino acid sequence of the homologous polypeptide corresponds to the sequence
of the activin chain when aligned to maximize the number of amino acid residue matches
between the two proteins. Alignment to maximize matches of residues includes shifting the
amino and/or carboxyl terminus, introducing gaps as required, and/or deleting residues present
as inserts in the candidate. Typically, amino acid sequence variants will be greater than
about 70% homologous with the corresponding native sequences.
While the site for introducing a sequence variation is predetermined, it is unnecessary
that the mutation per se be predetermined. For example, in order to optimize the
performance of mutation at a given site, random mutagenesis may be conducted at the target
codon or region and the expressed activin mutants screened for the optimal combination of
desired activity. Techniques for making substitution mutations at predetermined sites in DNA
having a known sequence are well known, for example, M13 primer mutagenesis.
Mutagenesis is conducted by making amino acid insertions, usually on the order of
about from 1 to 10 amino acid residues, or deletions of about from 1 to 30 residues.
Substitutions, deletions, insertions, or any subcombination may be combined to arrive at a
final construct. Preferably, however, substitution mutagenesis is conducted. Obviously, the
mutations in the encoding DNA must not place the sequence out of reading frame and
preferably will not create complementary regions that could produce secondary mRNA
Covalent modifications of activin are included within the scope of the invention, and
include covalent or aggregative conjugates with other chemical moieties. Covalent
derivatives are prepared by linkage of functionalities to groups that are found in the activin
amino acid side chains or at the N- or C-termini, by means known in the art. For example,
these derivatives will include: aliphatic esters or amides of the carboxyl terminus or residues
containing carboxyl side chains, e.g., aspartyl residues; O-acyl derivatives of hydroxyl group-
containing residues such as aryl or alanyl; and N-acyl derivatives of the amino terminal amino
acid or amino-group containing residues, e.g., lysine or arginine. The acyl group is selected
from the group of alkyl moieties (including C3 to CIO normal alkyl), thereby forming alkanoyl
species, and carbocyclic or heterocyclic compounds, thereby forming aroyl species. The
reactive groups preferably are difunctional compounds known per se for use in crosslinking
proteins to insoluble matrices through reactive side groups, e.g., m-maleimidobenzoyl-N-
hydroxy succinimide ester. Preferred derivatization sites are at histidine residues.
The expression "administering to the testis" means not only injection into the testis,
but also techniques that result in flooding the area surrounding the testis with activin such
that the activin is absorbed into the testis. In addition, the activin can be injected into a
vessel that feeds the testis, preferably using a microscopic procedure. Furthermore, the
activin can be put into an implant that is placed near the testis and through which the activin
is absorbed into the testis. Examples include an intratesticular long-acting depot (e.g.,
microsphere) or slow-release implant. Other techniques may be employed, provided that the
result is that activin is applied locally to the testis and is effective for the purposes stated
The expression "germinal epithelium failure" refers to disorders of male mammals that
may be characterized as complete or partial germinal epithelium failure, provided that some
5 spermatogonal stem cells are present, as determined, e.g., by a testis biopsy analysis.
Examples of such disorders include those characterized as partial germinal epithelium failure
as well as azoospermia presenting in patients who have some spermatogonal stem cells.
Complete failure is associated with high basal FSH levels.
The expression "partial germinal epithelium failure" refers to a disorder of mammals
1 0 that present with oligospermia and intact Leydig cell steroidogenic capacity and pituitary cells.
Such males have normal testosterone levels but low sperm counts. Most clinicians consider
a sperm density of less than 20 million/ml with adequate volume, motility and morphology
to indicate low sperm count. Sperm morphology is another indication, with one suggestion
that low sperm count is evidence when the percentage of abnormal spermatozoa is above 40.
15 The disorders characterized as partial germinal epithelium failure may be caused by
chemicals or drugs such as chemotherapeutic drugs and sulfa antibiotics, as well as alcohol
and illicit drugs. Other possible causes include genetic disorders, genital tract infections, and
varicoceles. The largest group of infertile men falls into the category of idiopathic
oligospermia, without an evident etiology. The need for an increase in fertility is generally
20 due to a primary testicular disorder, i.e., not at the hypothalamic or pituitary level.
The present invention concerns itself with using activin to increase fertility in male
mammals in the patient population identified above, including sports, zoo, pet, and farm
animals such as dogs, cats, cattle, pigs, horses, monkeys, and sheep, as well as humans.
Preferably the disorder is partial germinal epithelium failure.
25 The activin is administered to the mammal by any suitable technique, including
parenteral, sublingual, intratesticular, intrapulmonary, and intranasal administration. The
specific route of administration will depend, e.g., on the medical history of the patient.
Examples of parenteral administration include intramuscular, subcutaneous, intravenous,
intraarterial, and intraperitoneal administration. Preferably, the activin is administered via the
30 testis, as discussed above.
The activin compositions to be used in the therapy will be formulated and dosed in a
fashion consistent with good medical practice, taking into account the clinical condition of
the individual patient, the site of delivery of the activin composition, the method of
administration, the scheduling of administration, and other factors known to practitioners.
35 The "effective amount" for purposes herein is thus determined by such considerations.
As a general proposition, the total pharmaceutical^ effective amount of the activin
administered per dose will be in the range of about 1 //g/kg/day to 10 mg/kg/day of patient
body weight, although, as noted above, this will be subject to a great deal of therapeutic
WO 91/10444 PCI7US91/00074
discretion. Preferably, this dose is no more than about 10 //g/kg/day. The key factor in
selecting an appropriate dose is the result obtained, as measured by increases in sperm
density by serum analysis or the number of spermatocytes, or by other criteria as deemed
appropriate by the practitioner, e.g., biopsy.
5 For administration, the activin is formulated generally by mixing it at the desired degree
of purity, in a unit dosage injectable form (solution, suspension, or emulsion), with a
pharmaceutical^ acceptable carrier, i.e., one that is non-toxic to recipients at the dosages
and concentrations employed and is compatible with other ingredients of the formulation.
For example, the formulation preferably does not include oxidizing agents and other
1 0 compounds that are known to be deleterious to polypeptides.
Generally, the formulations are prepared by contacting the activin uniformly and
intimately with liquid carriers or finely divided solid carriers or both. Then, if necessary, the
product is shaped into the desired formulation. Preferably the carrier is a parenteral carrier,
more preferably a solution that is isotonic with the blood of the recipient. Examples of such
1 5 carrier vehicles include water, saline, Ringer's solution, and dextrose solution. Non-aqueous
vehicles such as fixed oils and ethyl oleate are also useful herein, as well as liposomes.
The carrier suitably contains minor amounts of additives such as substances that
enhance isotonicity and chemical stability. Such materials are non-toxic to recipients at the
dosages and concentrations employed, and include buffers such as phosphate, nitrate, and
20 other organic acid salts; antioxidants such as ascorbic acid; low molecular weight (less than
about ten residues) polypeptides, e.g., polyarginine or tripeptides; proteins, such as serum
albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone;
amino acids, such as glycine, glutamic acid, aspartic acid, or arginine,; monosaccharides,
disaccharides, and other carbohydrates including cellulose or its derivatives, glucose,
25 mannose, or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or
sorbitol; counterions such as sodium, and/or nonionic surfactants such as Tween, Pluronics,
The activin is typically formulated in such vehicles at a concentration of about 0.1
mg/ml to 100 mg/ml at physiological pH. It will be understood that use of certain of the
30 foregoing excipients, carriers, or stabilizers will result in the formation of activin salts.
Activin to be used for therapeutic administration must be sterile. Sterility is readily
accomplished by filtration through sterile filtration membranes (e.g., 0.2 micron membranes).
Therapeutic activin compositions generally are placed into a container having a sterile
access port, for example, a vial having a stopper pierceable by a hypodermic injection needle.
35 Activin ordinarily will be stored in unit or multi-dose containers, for example, sealed
ampoules or vials, as an aqueous solution or as a lyophilized formulation for reconstitute.
As an example of a lyophilized formulation, 10-ml vials are filled with 5 ml of sterile-filtered
1% (w/v) aqueous activin solution, and the resulting mixture is lyophilized. The infusion
solution is prepared by reconstituting the lyophilized activin using 5 ml of sterile water or
The activin is also suitably administered by sustained release systems. Suitable
examples of sustained release compositions include semi-permeable polymer matrices in the
5 form of shaped articles, e.g., films, or microcapsules. Sustained release matrices include
polyiactides (U.S. Pat. No. 3.773.919. EP 58.481), copolymers of L-glutamic acid and
gamma-ethyl-L-glutamate (U. Sidman et al., Biopolvmers. 2j>, 547-556 (1983H, poly(2-
hydroxyethyl methacrylate) (R. Langer et al., J. Biomed. Mater. Res. . i§ : 167-277 (1981).
and R. Langer, Chem. Tech., J2: 98-1 05 (1 982)). ethylene vinyl acetate (R. Langer et ah. IdJ
1 0 or poly-D-(-)-3-hydroxybutyric acid (EP 1 33,988). Sustained release activin compositions also
include liposomally entrapped activin. Liposomes containing activin are prepared by methods
known per se: DE 3,21 8, 1 2 1 ; Epstein et al., Proc. Natl. Arari. Sri U.S.A., fi2j 3688-3692
(1985); Hwang et al.. Proc. Natl. AraH s ff |, 1 1 g a yj. 4030-4034 (1980); EP 52,322; EP
36,676; EP 88.046; EP 143,949; EP 142,641; Japanese Pat. Appln. 83-118008; U.S. Pat.
1 5 Nos. 4,485.045 and 4.544,545; and EP 1 02.324. Ordinarily, the liposomes are of the small
(about 200-800 Angstroms) unilamellar type in which the lipid content is greater than about
30 mol. percent cholesterol, the selected proportion being adjusted for the optimal activin
Activin therapy is suitably combined with other proposed or conventional fertility
20 increasing therapies. For example, activin can be administered with other fertility agents used
to stimulate proliferation and differentiation of germ cells.
Examples of other therapies or agents include induction of rebound from testosterone
or anabolic androgen-induced azospermia; administration of exogenous gonadotropins or
gonadotropin releasing factors such as human chorionic gonadotropin (hCG), human
25 menopausal gonadotropin (hMG), purified FSH, or gonadotropin releasing hormone (GnRH).
Alteratively, ciomiphene citrate or tamoxifen may be used in conjunction with activin to
stimulate endogenous gonadotropin secretion. In addition, low doses of mesterolone, an oral
synthetic androgen, or an aromatase inhibitor such as testolactone may be administered.
The inhibin and fertility agents are suitably delivered by separate or the same means,
by separate or the same administration route, and at the same or at different times,
depending, e.g.. on dosing, the clinical condition of the patient, etc. It is not necessary that
such fertility agents be included in the activin compositions per se, although this will be
convenient where such drugs are delivered by the same administration route.
When employed together with the activin, such agents typically are employed in lesser
35 dosages than when used alone. If hCG is used, preferably the effective amount is 1 500 to
2000 I.U. twice weekly until testosterone levels are in the adult male range. At that point.
hMG in a dose of about one ampule every other day is also administered. |f ciomiphene
citrate therapy is employed, treatment is typically 25 mg of ciomiphene citrate daily for 21
to 25 days, followed by a 5- to 7-day rest period. This cycle is generally repeated for at least
A typical combined composition will contain the above-noted amount of activin and
about 25 mg of clomiphene citrate in a suitable intraperitoneal fluid such as lactated Ringer's
The invention will be more fully understood by reference to the following examples.
They should not however, be construed as limiting the scope of the invention.
Sertoli cells and germ cells from 20-day-old male Sprague-Dawley rats (Charles River
10 Laboratories, Inc., Wilmington, MA) were co-cultured in serum-free media. Cultures were
prepared according to the glycine/collagenase method described by Mather and Phillips in
Methods for Serum-Free Culture of C ells of the Endocrine System. Barnes and Sato eds. (Alan
R. Liss, inc.: New York, 1984), p. 29-45, and Rich et aL, Endocrinol. . 113 : 2284-2293
15 Briefly, testis were removed and decapsulated and the tubules teased apart in a
hypertonic glycine solution. The return of the tubules to isoosmotic medium results in lysis
of the interstitial tissue without harming the tubules. The tubules were then minced into
smaller segments and enzymatically treated with collagenase/dispase to remove the basement
membranes and peritubular cells. The peritubular cells were discarded and the tubular pieces
20 of 1-5 mm in length, which contain Sertoli cells and spermatogonia and spermatocytes, were
plated in serum-free Ham's F1 2/DME medium supplemented with HEPES and insulin, 5 //g/ml;
transferrin, 5 //g/ml; a-tocopherol, 5 ^g/ml; epidermal growth factor (EGF), 5ng/ml; and
aproteinin, 25 //g/ml (5F). After 20-24 hours the Sertoli cells had attached to the substrate
and spread to form a monolayer. Spermatocytes could be seen adhering to the monolayer
25 as single cells or groups of two cells or floating unattached in the medium.
At 24 hours after plating the medium was changed and unattached ceils were
discarded. Fresh 5F medium was added to all cultures, and additionally 100 ng/ml human
recombinant inhibin A or activin A (prepared and purified as described in U.S. Pat. No.
4,798,885 issued January 17, 1989) was added to the experimental conditions. All
30 conditions were assayed in triplicate and the entire experiment was repeated multiple (> 1 0)
Between 24 and 48 hours of treatment, clusters of spermatogonia and increased
numbers of primary spermatocytes appeared in the activin-treated wells. These cells appear
as connected clusters of 8-32 cells attached to the Sertoli cell monolayer and large cells in
35 suspension. No such effect was seen with inhibin.
Each well contained 2 million cells. A total of 1 //Ci of 3H-thymidine was added to
each well after 24, 48, or 72 hours of treatment with activin or inhibin.
WO 91/10444 PCT/US91/00074
Label incorporation into cells was measured after 20 hours of incubation with 3H-
thymidine. Cells were detached from the substrate by vigorous pipetting with a 1 ml
Pipettman™ pipettor. and the entire contents of the well was transferred to a 1 0-ml filter well
containing two glass fiber filters and 5 ml of cold 20% trichloroacetic acid. The precipitated
5 cells were caught on the filter and washed two times with cold 5% trichloroacetic acid to
remove unincorporated 3H-thymidine. Filters were washed once with cold methanol and
counted in a scintillation fluid appropriate for aqueous samples.
The results are shown in Figure 1 . Incorporation was higher in the activin-treated wells
compared with untreated control or inhibin-treated wells in all cases. At 48 hours of curturing
1 0 the activin was at its highest incorporation (1 1 ,040 cpm ±_ 1 572 SEM) relative to the control
(4515 .+ 597) and inhibin-treated cultures (5355 ± 466). Thus, activin increases the
proliferation of the spermatocytes.
The effect of inhibin and activin on germ cell differentiation was quantified by flow
cytometric analysis. Sertoli cells were stained with Nile red (a selective fluorescent stain for
intracellular lipid droplets) and non-staining germ cells were electronically gated. A DNA-
specific fluorochrome (Hoechst 33342) was used to determine the percentage of germ cells
with N, 2N or 4N DNA content, with 4N = primary spermatocytes. As seen from Figures 2A
and 2B, activin-treated cultures had a significant increase in the percentage of 4N germ cells
as compared with control or inhibin-treated cultures at 48 hours.
In conclusion, activin stimulates the proliferation and differentiation of 20-day old rat
testicular germ cells in vitro, indicating that it will increase fertility in the male. The data also
indicate that local administration of activin, being mitogenic for germ cells via, e.g., an
intratesticular depot method, would cause direct gonadal stimulation of sperm production,
independent of (or possibly in concert with) changes in gonadotropin secretion.
WHAT IS CLAIMED IS:
1 . A method of increasing fertility in a male mammal exhibiting germinal epithelium
failure comprising administering to the mammal an effective amount of activin.
2. The method of claim 1 wherein the activin is porcine or human activin A, activin
AB, or activin B.
3. The method of claim 2 wherein the activin is human activin A.
4. The method of claim 1 wherein the administration is to the testis.
5. The method of claim 4 wherein the administration is by injection into the testis.
6. The method of claim 1 wherein the mammal is human.
7. The method of claim 1 wherein the effective amount is a daily dose of about 1
pg/kQ to 10 mg/kg.
8. The method of claim 1 wherein the germinal epithelium failure is partial germinal
9. A pharmaceutical composition for increasing fertility in male mammals exhibiting
germinal epithelium failure comprising an effective amount of activin in a pharmaceutical^
10. The composition of claim 9 wherein the activin is porcine or human activin A f
activin AB, or activin B.
1 1 . The composition of claim 10 that contains human activin A.
12. The composition of claim 9 wherein the carrier is sterile water, a buffer, or
1 / 1
FIG. 1 ,5fi0 *
C = CONTROL
I = INHIBIN
C = CONTROL
I = ACTIVIN
INTERNATIONAL SEARCH REPORT
InUmatlonal Aepllcatlon No PCT/US 91/00074
1. CLASSIFICATION OF SUBJECT MATTER (If intra! da ittfi cation symbols apply. Indicate alt) •
According to International Patsnt Classification (IPC) or to both National Classification and IPC
IPC 5 : A 61 K 37/43
11. FIELDS SEARCHED
Minimum Documentation Ssarchtd »
A 61 K, C 07 K'
Documentation Ssarchtd othar than Minimum Documentation
to the Extant that such Oocumants art Included In the Fltlds Sesrched •
111. DOCUMENTS CONSIDERED TO BE RELEVANT *
Citation ot Document, " with Indication, where appropriate, of the rtlevant passages '*
Relevant to Claim No. "
US, A, 4864019 (WYLIE W. VALE et al. )
5 September 1989
• Special categories of cited documents: *e
"A" document defining the general state of the art which la not
considered to be of particular relevance
"E" earlier document but published on or after the International
*L" document which may throw doubts on priority clalm(a) or
which Is cited to establish ths publication date of another
citation or ether special reason (ss specified)
*0" document referring to an oral disclosure, use, exhibition or
-P" document published prior to the international filing date but
later than the priority date claimed
"T" later document p utile bed attar the International filing date
or priority date and not In conflict with the application but
cited to understand the principle or theory underlying the
"X" document of particular relevance; the claimed Invention
cannot be considsrad novel or cannot be conaldered to
involve an Inventive atep
•Y" document of particular relevance;' the claimed Invention
cannot be conaldered to Invohre an Inventive sttp when the
document la combined with one or more other such docu-
ments, such combination being obvious to a peraon skilled
in the art
document member of the same patent family
Oil* o< th. Actual Completion of tho InUrnatloiul Soarch
16th April 1991
Data of Mailing of this International Search Report
International Searching Authority
EUROPEAN PATENT OFFICE
^jgnatn ol Authoriiad Ofllcir
(jjtJlCU13 Danielle van der Haas
Form PCT /ISA/210 1 second sheet) (January 1615)
International Application No. PCT/US 91/00074
FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET
V.K] OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE 1
This Internationa ( search report haa not be*n established in respect of certain dalma under Article 17(2) (a) for the following reaaons:
Claim numbers . !./„.??., because they relate to subject matter not required to be searched by this Authority, namely:
Please see Rule 39.1 (iv): methods for treatment of the
human or animal body by surgery or therapy, as well as
2.n Claim numbers , becauae they relate to parts of the International application that do not comply with the prescribed require*
ments to such an extent that no meaningful international search can be carried out. spectneally :
3 J | Claim numbers because they are dependent claims and are not drafted hi accordance with the aecond and third sentences of
VlQ OBSERVATIONS WHERE UNITY OF INVENTION 18 LACKING -
This International Searching Authority found multiple Inventions In thla International application as follows:
As all required additional search fees were timely paid by the applicant, this International search report covers all searchable dalma
of the International application,
2Q As only some of the required additional search fees were timely paid by the applicant, this International search report covers only
those claims of the International application for which fees were paid, specifically claims;
No required additional search fees were timely paid by the applicant Consequently, this international search report la restricted to
the Invention first mentioned In the claims; It Is covered by claim numbers:
4.| | As all •earchable claims could be searched without effort justifying an additional fee* the International Searching Authority did not
— invite payment of any additional fee.
Remark on Protest
Q The additional search fees were accompanied by applicant's protest
n No protest accompanied the payment of eddtttonal aearch teea.
Form PCT /IS A/210 (supplements! sheet (2)) (January 1985)
ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO. US 9100074
This annex lists the patent family members relatmg to the patent documents cited in the above-mentioned internatioaal search report.
The members are as contained in the European Patent Office EDP file on 27/05/91
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.
cited in search report
w For more details about this annex : see Official Jearaal of the European Patent Office, No. 12/82
This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record
BEST AVAILABLE IMAGES
Defective images within this document are accurate representations of the original
documents submitted by the applicant.
Defects in the images include but are not limited to the items checked:
□ BLACK BORDERS
□ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
Of FADED TEXT OR DRAWING
[^BLURRED OR ILLEGIBLE TEXT OR DRAWING
□ SKEWED/SLANTED IMAGES
□ COLOR OR BLACK AND WHITE PHOTOGRAPHS
□ GRAY SCALE DOCUMENTS
□ LINES OR MARKS ON ORIGINAL DOCUMENT
□ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
IMAGES ARE BEST AVAILABLE COPY.
As rescanning these documents will not correct the image
problems checked, please do not report these problems to
the IFW Image Problem Mailbox.